QUEBEC CITY, April 29, 2013 /PRNewswire/ - DiagnoCure Inc.
(TSX: CUR) (OTCQX: DGCRF) reminds shareholders to attend its Annual
and Special Meeting of Shareholders to be held today, April 29th, at 3pm EDT, at the offices of McCarthy Tetrault,
1000 de la Gauchetière Street West, Suite 2500, Montreal, Quebec, H3B 0A2.
At the completion of the formal business portion
of the meeting, Dr. Yves Fradet,
President and Chief Medical Officer will make a presentation during
which he will touch upon the following topics:
- An update on the Corporation's current status of the GCC and
PCA3 products;
- A review of the Corporation's business model evolution;
- Initiation of a search for a full-time CEO to achieve maximum
leverage from DiagnoCure's product development platform.
The presentation will be available on
DiagnoCure's website at www.diagnocure.com through a link on the
Investors page; presentations, available from 3pm for those unable to attend the meeting.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life
sciences corporation that develops and commercializes high-value
cancer diagnostic tests that increase clinician and patient
confidence in making critical treatment decisions. In 2008, the
Corporation launched a colorectal cancer staging test through its
U.S. CLIA laboratory. PrevistageTM GCC is currently
available for licensing. The Corporation has granted a worldwide
exclusive license to Gen-Probe, now a wholly-owned subsidiary of
Hologic Inc. operating as Hologic Gen-Probe, for the development
and commercialization of a prostate cancer test using PCA3,
DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and
the United States. For more
information, please visit www.diagnocure.com.
Forward‐looking statements
This release may contain forward‐looking
statements that involve known and unknown risks, uncertainties and
assumptions that may cause actual results to differ materially from
those expected. Forward-looking statements can be identified by the
use of the conditional or forward-looking terminology such as
"anticipates", "assumes", "believes", "estimates", "expects",
"intend", "may", "plans", "projects", "should", "will", or the
negative thereof or other variations thereon. Forward-looking
statements also include any other statements that do not refer to
historical facts. All such forward-looking statements are made
pursuant to the "safe-harbour" provisions of applicable Canadian
securities laws. By their very nature, forward‐looking statements
are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond
DiagnoCure's control. Forward-looking statements are presented for
the purpose of assisting investors and others in understanding
certain key elements of the Corporation's current objectives,
strategic priorities, expectations and plans, and in obtaining a
better understanding of the Corporation's business and anticipated
operating environment. Readers are cautioned that such information
may not be appropriate for other purposes and that they should not
place undue reliance on these forward‐looking statements. For
instance, any forward-looking statements regarding the outcome of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA® PCA3, are
based on management expectations and such outcome may vary
materially depending on global political and economic conditions,
dependence on collaboration partners, uncertainty of healthcare
reimbursement, and marketing and distribution challenges. In
addition, the reader is referred to the applicable general risks
and uncertainties described in DiagnoCure's most recent Annual
Information Form under the heading "Risk Factors". DiagnoCure
undertakes no obligation to publicly update or revise any
forward‐looking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DiagnoCure inc.
